IL139478A0 - Hybrid protein - Google Patents
Hybrid proteinInfo
- Publication number
- IL139478A0 IL139478A0 IL13947899A IL13947899A IL139478A0 IL 139478 A0 IL139478 A0 IL 139478A0 IL 13947899 A IL13947899 A IL 13947899A IL 13947899 A IL13947899 A IL 13947899A IL 139478 A0 IL139478 A0 IL 139478A0
- Authority
- IL
- Israel
- Prior art keywords
- hybrid protein
- mastocytes
- basophils
- protein
- splits
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 210000003651 basophil Anatomy 0.000 abstract 2
- 210000003630 histaminocyte Anatomy 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000003248 secreting effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to a hybrid protein comprising or comprised of (i) a known protein which binds to mastocytes and/or basophils in a known manner and/or is absorbed thereby, and of (ii) a protease which splits one or more proteins of the secretory apparatus of the mastocytes and/or basophils.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19821285 | 1998-05-13 | ||
PCT/EP1999/003272 WO1999058571A2 (en) | 1998-05-13 | 1999-05-12 | Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IL139478A0 true IL139478A0 (en) | 2001-11-25 |
Family
ID=7867540
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13947899A IL139478A0 (en) | 1998-05-13 | 1999-05-12 | Hybrid protein |
IL139478A IL139478A (en) | 1998-05-13 | 2000-11-05 | Hybrid protein for inhibiting the degranulation of mastoctes and the use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL139478A IL139478A (en) | 1998-05-13 | 2000-11-05 | Hybrid protein for inhibiting the degranulation of mastoctes and the use thereof |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1084146B1 (en) |
JP (1) | JP4549533B2 (en) |
KR (1) | KR100580541B1 (en) |
CN (1) | CN1241945C (en) |
AT (1) | ATE227739T1 (en) |
AU (1) | AU755513B2 (en) |
BR (1) | BR9910359A (en) |
CA (1) | CA2331274C (en) |
CU (1) | CU22997A3 (en) |
CZ (1) | CZ294376B6 (en) |
DE (1) | DE59903410D1 (en) |
DK (1) | DK1084146T3 (en) |
ES (1) | ES2187200T3 (en) |
HK (1) | HK1036994A1 (en) |
HU (1) | HUP0103601A3 (en) |
IL (2) | IL139478A0 (en) |
MX (1) | MXPA00011148A (en) |
NO (1) | NO328361B1 (en) |
PL (1) | PL201879B1 (en) |
PT (1) | PT1084146E (en) |
RU (1) | RU2214420C2 (en) |
WO (1) | WO1999058571A2 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
US20040071736A1 (en) | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
US20080038274A1 (en) | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
GB9922554D0 (en) * | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
EP1365800B1 (en) * | 2000-06-28 | 2013-03-06 | Ira Sanders | Methods for using tetanus toxin for benificial purposes in animals (mammals) |
GB0321344D0 (en) * | 2003-09-11 | 2003-10-15 | Health Prot Agency | Re-targeted toxin conjugates |
GB0426394D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
KR100845278B1 (en) * | 2006-08-04 | 2008-07-09 | 포항공과대학교 산학협력단 | Peptide for activating mast cell and immunomodulator comprising the same |
EP2719392B1 (en) | 2008-06-12 | 2019-07-24 | Ipsen Bioinnovation Limited | Fusion proteins for use in the treatment of acromegaly |
BRPI0915142A8 (en) | 2008-06-12 | 2018-01-02 | Syntaxin Ltd | POLYPEPTIDES, NUCLEIC ACID AND USES THEREOF |
US8735133B2 (en) * | 2008-07-31 | 2014-05-27 | Total Marketing Services | Constructs and methods for the production and secretion of polypeptides |
GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
CN102241774B (en) * | 2010-05-27 | 2014-05-14 | 四川大学 | Recombinant IgE-Fc-anti EGFR single chain variable fragment fusion protein, its preparation method and its application |
GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
US20140056870A1 (en) | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
PL3242884T3 (en) | 2015-01-09 | 2021-08-16 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
EP3263710A1 (en) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
BR112023018473A2 (en) | 2021-03-30 | 2023-11-14 | Ipsen Biopharm Ltd | CATALYTICALLY INACTIVE CLOSTRIDIAL NEUROTOXINS FOR THE TREATMENT OF PAIN AND INFLAMMATORY DISORDERS |
KR20230163470A (en) | 2021-03-30 | 2023-11-30 | 입센 바이오팜 리미티드 | Treatment of pain & inflammatory disorders |
GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
PL244930B1 (en) | 2021-12-08 | 2024-04-02 | Gdanski Univ Medyczny | Use of 2-methoxyestradiol in the treatment of mastocytosis |
GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9305735D0 (en) * | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
IL116436A (en) * | 1995-12-18 | 2006-12-31 | Yissum Res Dev Co | Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND |
-
1999
- 1999-05-12 DE DE59903410T patent/DE59903410D1/en not_active Expired - Lifetime
- 1999-05-12 AU AU42605/99A patent/AU755513B2/en not_active Ceased
- 1999-05-12 CA CA2331274A patent/CA2331274C/en not_active Expired - Fee Related
- 1999-05-12 BR BR9910359-1A patent/BR9910359A/en not_active Application Discontinuation
- 1999-05-12 RU RU2000131217/04A patent/RU2214420C2/en not_active IP Right Cessation
- 1999-05-12 KR KR1020007011584A patent/KR100580541B1/en not_active IP Right Cessation
- 1999-05-12 MX MXPA00011148A patent/MXPA00011148A/en not_active IP Right Cessation
- 1999-05-12 HU HU0103601A patent/HUP0103601A3/en unknown
- 1999-05-12 CN CNB998060615A patent/CN1241945C/en not_active Expired - Fee Related
- 1999-05-12 EP EP99950347A patent/EP1084146B1/en not_active Expired - Lifetime
- 1999-05-12 JP JP2000548373A patent/JP4549533B2/en not_active Expired - Fee Related
- 1999-05-12 IL IL13947899A patent/IL139478A0/en active IP Right Grant
- 1999-05-12 PT PT99950347T patent/PT1084146E/en unknown
- 1999-05-12 ES ES99950347T patent/ES2187200T3/en not_active Expired - Lifetime
- 1999-05-12 DK DK99950347T patent/DK1084146T3/en active
- 1999-05-12 AT AT99950347T patent/ATE227739T1/en active
- 1999-05-12 CZ CZ20004161A patent/CZ294376B6/en not_active IP Right Cessation
- 1999-05-12 WO PCT/EP1999/003272 patent/WO1999058571A2/en active IP Right Grant
- 1999-05-12 PL PL344752A patent/PL201879B1/en not_active IP Right Cessation
-
2000
- 2000-10-30 CU CU20000234A patent/CU22997A3/en not_active IP Right Cessation
- 2000-11-05 IL IL139478A patent/IL139478A/en not_active IP Right Cessation
- 2000-11-08 NO NO20005637A patent/NO328361B1/en not_active IP Right Cessation
-
2001
- 2001-09-21 HK HK01106685A patent/HK1036994A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2214420C2 (en) | 2003-10-20 |
CN1300295A (en) | 2001-06-20 |
JP2002514659A (en) | 2002-05-21 |
KR20010042825A (en) | 2001-05-25 |
ES2187200T3 (en) | 2003-05-16 |
HUP0103601A2 (en) | 2002-01-28 |
DE59903410D1 (en) | 2002-12-19 |
EP1084146A2 (en) | 2001-03-21 |
CZ294376B6 (en) | 2004-12-15 |
EP1084146B1 (en) | 2002-11-13 |
HUP0103601A3 (en) | 2004-06-28 |
NO20005637D0 (en) | 2000-11-08 |
JP4549533B2 (en) | 2010-09-22 |
CA2331274C (en) | 2010-04-06 |
AU755513B2 (en) | 2002-12-12 |
BR9910359A (en) | 2001-01-09 |
NO20005637L (en) | 2000-11-08 |
PL344752A1 (en) | 2001-11-19 |
WO1999058571A2 (en) | 1999-11-18 |
CU22997A3 (en) | 2004-10-12 |
CA2331274A1 (en) | 1999-11-18 |
IL139478A (en) | 2008-06-05 |
DK1084146T3 (en) | 2003-02-03 |
CN1241945C (en) | 2006-02-15 |
WO1999058571A3 (en) | 2000-02-03 |
AU4260599A (en) | 1999-11-29 |
CZ20004161A3 (en) | 2001-04-11 |
HK1036994A1 (en) | 2002-01-25 |
PL201879B1 (en) | 2009-05-29 |
PT1084146E (en) | 2003-02-28 |
ATE227739T1 (en) | 2002-11-15 |
KR100580541B1 (en) | 2006-05-16 |
MXPA00011148A (en) | 2003-04-22 |
NO328361B1 (en) | 2010-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL139478A0 (en) | Hybrid protein | |
EP0783527A4 (en) | Cathepsin o2 protease | |
EP1712623A3 (en) | Selection of proteins using RNA-protein fusions | |
WO2000023564A3 (en) | Protein design automation for protein libraries | |
YU9404A (en) | Peptide-based multimeric targeted contrast agents | |
ES2149149T1 (en) | INTERLEUKIN-18 FIXING PROTEINS, THEIR PREPARATION AND USE. | |
MY113489A (en) | Reversible protease inhibitors | |
AU2002217010A1 (en) | Peptides, the production and use thereof for binding immunoglobulins | |
IL145689A0 (en) | Methods | |
EP0626450A3 (en) | Ubiquitin conjugating enzyme (E2) fusion proteins. | |
FR2816410B1 (en) | ESM-1 PROTEIN DETECTION KIT AND DETECTION METHOD USING THE SAME | |
AU2001238212A1 (en) | Modified fluorescent proteins | |
WO1997045746A3 (en) | Prion protein binding proteins and uses thereof | |
DE69634077D1 (en) | HAEMOPHILUS ADHESION PROTEINS | |
PT723552E (en) | OLIGOPEPTIDES DERIVED FROM REAGENT PROTEIN FRAGMENTS | |
DE60023933D1 (en) | Hybrid-toxine von bacillus thuringiensis | |
DE69737457D1 (en) | O-fucosyltransferase | |
AU5178698A (en) | Novel serine protease inhibitor nucleic acid molecules, proteins and uses hereof | |
DK1002056T3 (en) | ppGpp synthase and expression system for improved production of protein of interest | |
EP0846165A4 (en) | Novel filariid nematode cysteine protease proteins, nucleic acid molecules and uses thereof | |
BG102937A (en) | Zona pelucida proteins as contraceptives | |
ZA200007619B (en) | New peptide fragments for protein purification. | |
WO1998030687A3 (en) | Protein containing an srcr domain | |
SE9604439D0 (en) | New receptor | |
WO2003027139A3 (en) | Novel purified polypeptides involved in membrane biosynthesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
FF | Patent granted |